OncoZenge AB (publ) (ONCOZ.ST)
SEK 5.11
(2.0%)
SEK 5.11
(2.0%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 15.9 Million SEK | -63.49% |
| 2022 | 43.56 Million SEK | 790.44% |
| 2021 | 4.89 Million SEK | 510.86% |
| 2020 | 801 Thousand SEK | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 2.37 Million SEK | -25.31% |
| 2024 Q2 | 2.04 Million SEK | -13.5% |
| 2023 Q1 | 4.05 Million SEK | -11.02% |
| 2023 FY | 15.9 Million SEK | -63.5% |
| 2023 Q3 | 4.18 Million SEK | -6.79% |
| 2023 Q2 | 4.49 Million SEK | 10.83% |
| 2023 Q4 | 3.17 Million SEK | -24.22% |
| 2022 Q4 | 4.55 Million SEK | 42.03% |
| 2022 FY | 43.56 Million SEK | 790.44% |
| 2022 Q3 | 3.2 Million SEK | 13.64% |
| 2022 Q2 | 2.82 Million SEK | -91.44% |
| 2022 Q1 | 32.98 Million SEK | 2302.4% |
| 2021 Q3 | 987 Thousand SEK | -10.92% |
| 2021 Q2 | 1.1 Million SEK | -22.25% |
| 2021 Q1 | 1.42 Million SEK | 0.0% |
| 2021 Q4 | 1.37 Million SEK | 39.11% |
| 2021 FY | 4.89 Million SEK | 510.86% |
| 2020 FY | 801 Thousand SEK | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | 1.51 Billion SEK | 98.95% |
| AcouSort AB (publ) | 25.87 Million SEK | 38.534% |
| Active Biotech AB (publ) | 44.8 Million SEK | 64.505% |
| Alzinova AB (publ) | 36.39 Million SEK | 56.3% |
| Amniotics AB (publ) | 29.07 Million SEK | 45.291% |
| Asarina Pharma AB (publ) | 14.65 Million SEK | -8.544% |
| BioArctic AB (publ) | 89.62 Million SEK | 82.254% |
| Camurus AB (publ) | 1.05 Billion SEK | 98.499% |
| Cantargia AB (publ) | 290.01 Million SEK | 94.516% |
| Scandinavian ChemoTech AB (publ) | 21.89 Million SEK | 27.358% |
| Elicera Therapeutics AB (publ) | 28.32 Million SEK | 43.851% |
| Genovis AB (publ.) | 88.19 Million SEK | 81.967% |
| Guard Therapeutics International AB (publ) | 115.07 Million SEK | 86.178% |
| Mendus AB (publ) | 129.13 Million SEK | 87.684% |
| Kancera AB (publ) | 63.07 Million SEK | 74.785% |
| Karolinska Development AB (publ) | 5.51 Million SEK | -188.186% |
| LIDDS AB (publ) | 27.75 Million SEK | 42.689% |
| Lipum AB (publ) | 37.3 Million SEK | 57.367% |
| Lipigon Pharmaceuticals AB (publ) | 7.25 Million SEK | -119.258% |
| Magle Chemoswed Holding AB (publ) | 135.91 Million SEK | 88.298% |
| Modus Therapeutics Holding AB (publ) | 16.4 Million SEK | 3.024% |
| NextCell Pharma AB | -576.01 Thousand SEK | 2861.194% |
| Saniona AB (publ) | 1.07 Million SEK | -1376.787% |
| Simris Alg AB (publ) | 38.64 Million SEK | 58.84% |
| Vicore Pharma Holding AB (publ) | 321.5 Million SEK | 95.053% |
| Xbrane Biopharma AB (publ) | 357.62 Million SEK | 95.553% |
| Xintela AB (publ) | 57.31 Million SEK | 72.25% |
| Ziccum AB (publ) | 27.87 Million SEK | 42.948% |
| Isofol Medical AB (publ) | 7.26 Million SEK | -118.836% |
| Xspray Pharma AB (publ) | 181.73 Million SEK | 91.248% |
| CombiGene AB (publ) | 44.14 Million SEK | 63.97% |
| Diamyd Medical AB (publ) | 142.98 Million SEK | 88.877% |
| Intervacc AB (publ) | 79.78 Million SEK | 80.065% |
| Alligator Bioscience AB (publ) | 307.09 Million SEK | 94.821% |
| Sprint Bioscience AB (publ) | 42.63 Million SEK | 62.692% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | 17.68 Million SEK | 10.055% |
| Corline Biomedical AB | 30.16 Million SEK | 47.279% |
| IRLAB Therapeutics AB (publ) | 58.03 Million SEK | 72.592% |
| Bio-Works Technologies AB (publ) | 83.16 Million SEK | 80.876% |
| Aptahem AB (publ) | 10.01 Million SEK | -58.844% |
| Infant Bacterial Therapeutics AB (publ) | 134.69 Million SEK | 88.192% |
| Fluicell AB (publ) | 28.61 Million SEK | 44.421% |
| Biovica International AB (publ) | 133.72 Million SEK | 88.106% |
| Spago Nanomedical AB (publ) | 19.79 Million SEK | 19.631% |
| Abliva AB (publ) | 27.86 Million SEK | 42.923% |
| Egetis Therapeutics AB (publ) | 193.5 Million SEK | 91.78% |
| 2cureX AB (publ) | 36.51 Million SEK | 56.446% |
| I-Tech AB | 40.14 Million SEK | 60.384% |
| Hansa Biopharma AB (publ) | 859.44 Million SEK | 98.149% |
| Cyxone AB (publ) | 28.21 Million SEK | 43.627% |
| ExpreS2ion Biotech Holding AB (publ) | 109.36 Million SEK | 85.457% |
| Biosergen AB | 26.8 Million SEK | 40.673% |
| Nanologica AB (publ) | 69.88 Million SEK | 77.242% |
| SynAct Pharma AB | 224.49 Million SEK | 92.915% |
| Annexin Pharmaceuticals AB (publ) | 44.17 Million SEK | 63.996% |
| BioInvent International AB (publ) | 441.4 Million SEK | 96.397% |
| Stayble Therapeutics AB (publ) | 23.95 Million SEK | 33.603% |
| Oncopeptides AB (publ) | 289.74 Million SEK | 94.511% |
| Pila Pharma AB (publ) | 7.85 Million SEK | -102.45% |
| Ascelia Pharma AB (publ) | 110.91 Million SEK | 85.66% |
| Diagonal Bio AB (publ) | 14.7 Million SEK | -8.197% |